An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-21

Study Completion Date

2029-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to seek an alternative, to anticoagulant medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

NCT05224375

Atrial Fibrillation

COMPLETED NA

Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System

NCT04807283

Atrial Fibrillation

UNKNOWN NA

Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events

NCT04559243

Non-valvular Atrial Fibrillation Embolic Stroke

RECRUITING

Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation

NCT02105584

Atrial Fibrillation

COMPLETED NA

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

NCT02583178

Atrial Fibrillation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Left atrial appendage closure (LAAC) is an approved therapy for stroke prevention in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy (OAC), but are non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants in accordance with evidence-based decision-making criteria and current scientific guidelines.

The objective of this study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism.

Patients will be followed for 5 years after the procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-valvular Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.

Group Type EXPERIMENTAL

Left Atrial Appendage Closure

Intervention Type DEVICE

Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Left Atrial Appendage Closure

Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented non-valvular AF, defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve.
2. Subject ≥18 years old.
3. CHA2DS2-VASc score ≥ 2 in men and ≥ 3 in women.
4. Subject is recommended for chronic oral anticoagulation therapy (OAC) but is not eligible or has an appropriate rationale to seek a non-pharmacologic alternative to chronic OAC.
5. Subject deemed appropriate for LAA closure by the Site Heart Team using an evidenced based decision-making tool.
6. Subject eligible for the protocol-specified post-procedural antithrombotic regimen.
7. Subject or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements.

Exclusion Criteria

1. Single episode, transient, or reversible AF (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures).
2. Stroke or transient ischemic attack within 90 days before the index procedure.
3. Myocardial infarction or unstable angina within 90 days before the index procedure.
4. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, or dialysis at the time of screening.
5. Active infection with bacteremia.
6. Confirmed COVID-19 infection within 10 days before the index procedure. Coexisting Cardiovascular Disease
7. Cardiac tumor
8. History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve.
9. Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve).
10. Severe heart failure (New York Heart Association Class IV).
11. Symptomatic carotid artery disease (\>50% diameter reduction with prior ipsilateral stroke or TIA) or asymptomatic carotid artery disease (diameter reduction of \>70%).

Previous or Planned Interventions
12. Previous AF ablation procedure in the 90 days before the index procedure date or need for AF ablation to be performed in less than 90 days after the index procedure.
13. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac or non-cardiac interventional or surgical procedure.
14. Intracardiac thrombus or dense spontaneous echo contrast visualized by TEE within 2 days before the index procedure.
15. Left ventricular ejection fraction (LVEF) \<30%.
16. Circumferential pericardial effusion \>10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology.
17. Complex atheroma with mobile plaque of the aorta.
18. Interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure.
19. Vascular access precluding delivery of implant with catheter-based system
20. Presence of inferior vena cava (IVC) filter that would interfere with Laminar sheath insertion.
21. Subject unable to undergo general anesthesia.
22. Subject with condition which precludes adequate transesophageal echocardiographic (TEE) assessment.
23. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium).
24. Contrast sensitivity that cannot be adequately pre-medicated.
25. Bleeding diathesis or coagulopathy
26. Thrombocytopenia (platelet count \<75,000 cells/mm3), thrombocytosis (\>700,000 cells/mm3), or leukopenia (white blood cell count \<3,000 cells/mm3).
27. Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Subjects of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure.
28. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year.
29. Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No